Influence of oral contraceptive pills on homocysteine and nitric oxide levels: As risk factors for cardiovascular disease

Journal of Clinical Laboratory Analysis

Volumn 26, Issue 2, 2012, Pages 120-123

  Fallah, Soudabeh ^a   Nouroozi, Vajihe ^a   Seifi, Morteza ^a,b   Samadikuchaksaraei, Ali ^a,d   Aghdashi, Elaheh Mokhtarned ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b University of Medical Science   (Iran)

^c SHARIF UNIVERSITY OF TECHNOLOGY   (Iran)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Atherosclerosis; Contraceptive pill; Homocysteine; Nitric oxide

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; HOMOCYSTEINE; NITRIC OXIDE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MENSTRUAL CYCLE; NORMAL HUMAN; RISK FACTOR; SIDE EFFECT; VASCULAR ENDOTHELIUM;

ADULT; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; DOSAGE FORMS; FEMALE; HOMOCYSTEINE; HUMANS; NITRIC OXIDE; RISK FACTORS; YOUNG ADULT;

EID: 84859180036     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21492     Document Type: Article

References (22)

1. Fallah S, Valinejad- Sani F, Firoozrai M. Effect of contraceptive pills on the activity status of the antioxidant enzymes glutathione peroxidase and superoxide's in healthy subjects. Contraception 2011;83(4):385-389.
2. Gabriele S, Merki F, Bruno I, Paul JK. Effects of oral contraceptives on plasma levels of nitric oxide, homocysteine and lipid metabolis. Metabolism 2002;51:1216-1221.
3. Hanna B, Stanislaw S, Ewa Z, Barbara M, Krzysztof S, Kornel C, Marek N. Dose the type of hormone replacement therapy affect lipoprotein (a), homocysteine and C-reactive protein levels in postmenopausal women? Metabolism 2005;54:72-78.
4. Ridker PM. High-sensitivity C-reactive protein: potential adjust risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-1818.
5. Boger RH, Lentz SR, Bode-Boger SM, et al. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci 2001;100:161-167.
6. Markus H, Omid TS, Ulrich H, Michael B, Wolfgang H. A review of homocysteine and heart failure. Eur J Heart Fail 2006;8(6):571-576.References [6, 13, 15, 17, and 18] have not been cited in the text. Please indicate where they should be cited; or delete them from the Reference List.
7. Hauschka PV, Damouils PD. Functions of nitric oxide in bone. Biochem Soc Trans 1998;26:39-44.
8. Vallance P, Hingorani A. Endothelial nitric oxide in humans in health and disease. Int J Exp Pathol 1999;80:303-655.
9. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997;96:2542-2544.
10. Michael FE, Diejomaoh, Alexander E, Sami T, Nasser A, Tunder F, Sanjit F, SAed A. Nitric oxide metabolites in preterm and induced labor. Gynecol Obstet Invest 2003;56(4):197-202.
11. Ridker PM, Manson JE, Shih J, Matias M, Hennekens CH. Homocysteine and risk cardiovascular disease among postmenopausal women. JAMA 1999;281:1817-1821.
12. Hak AE, Polderman KH, Westendorp IC, Jakob C, Hofman A, Witteman JC, Stehouwer CD. Increased plasma homocysteine after menopause. Atherosclerosis 2000;149:163-168.
13. Kleinert H, Wallerath T, Euchenhofer C, Ihriq-Biedert, Li H, Forstermann U. Estrogens increase transcription of the human endothelial NO synthase gene: Analysis of the transcription factors involved. Hypertension 1998;31:582-588.
14. Kilicdaq Eb, Baqis T, Zeyneloqlu HB, Tarim E, Aslan E, Haydardedeoglu B, Erkanli S. Homocyateine levels in women with polycystic ovay syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 2005;20:894-899.
15. Mayer O Jr, Simon J, Rosolová H. Gender differences in serum homocysteine levels and associated factors. Cas Lek Cesk 1999;138:525-527.
16. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999;19:217-246.
17. Diejomaoh MFE, Omu AE, Taher S, Al-Busiri N, Fatinikun T, Fernandes S, Al-Othman S. Nitric oxide metabolites in preterm and induced labor. Gynecol Obstet Invest 2003;56:197-202.
18. Tawako A, Omland T, Gerhard M, Wu JT, Creaqer MA. Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997;95:1119-1121.
19. Chow K, Cheung F, Lao TT. Effect of homocysteine on the production of nitric oxide in endothelial cells. Clin Exp Pharmacol Physiol 1999;26:817-818.
20. Groot De, Willems C, Boers GH, Gonsalves MD, Van Aken WG, Van Mourik JK. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest 1983;13:405-410.
21. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vase Biol 2000;20:1557-1564.
22. Merki-Feld GS, Imthurn B, Keller PJ. Effects of two oral contraceptives on plasma levels of nitric oxide, homocysteine, and lipid metabolism 2002; 51(9):1216-1221.